391 related articles for article (PubMed ID: 29125182)
1. Circulating microRNAs as potential biomarkers in myasthenia gravis patients.
Punga AR; Punga T
Ann N Y Acad Sci; 2018 Jan; 1412(1):33-40. PubMed ID: 29125182
[TBL] [Abstract][Full Text] [Related]
2. Circulating miRNAs as Potential Biomarkers in Myasthenia Gravis: Tools for Personalized Medicine.
Sabre L; Punga T; Punga AR
Front Immunol; 2020; 11():213. PubMed ID: 32194544
[TBL] [Abstract][Full Text] [Related]
3. Estrogen Receptor, Inflammatory, and FOXO Transcription Factors Regulate Expression of Myasthenia Gravis-Associated Circulating microRNAs.
Fiorillo AA; Heier CR; Huang YF; Tully CB; Punga T; Punga AR
Front Immunol; 2020; 11():151. PubMed ID: 32153563
[TBL] [Abstract][Full Text] [Related]
4. Disease specific enrichment of circulating let-7 family microRNA in MuSK+ myasthenia gravis.
Punga T; Bartoccioni E; Lewandowska M; Damato V; Evoli A; Punga AR
J Neuroimmunol; 2016 Mar; 292():21-6. PubMed ID: 26943954
[TBL] [Abstract][Full Text] [Related]
5. Differential Expression of miRNA in the Peripheral Blood Mononuclear Cells in Myasthenia Gravis with Muscle-Specific Receptor Tyrosine Kinase Antibodies.
Tan Y; Zhu L; Cui L; Guan Y
Crit Rev Eukaryot Gene Expr; 2021; 31(2):1-15. PubMed ID: 34347975
[TBL] [Abstract][Full Text] [Related]
6. Circulating miRNAs drive personalized medicine based on subgroup classification in myasthenia gravis patients.
Huang X; Zhang Z; Wang Y; Xu M; Du X; Zhang Y
Neurol Sci; 2023 Nov; 44(11):3877-3884. PubMed ID: 37402938
[TBL] [Abstract][Full Text] [Related]
7. Circulating microRNA miR-21-5p, miR-150-5p and miR-30e-5p correlate with clinical status in late onset myasthenia gravis.
Sabre L; Maddison P; Sadalage G; Ambrose PA; Punga AR
J Neuroimmunol; 2018 Aug; 321():164-170. PubMed ID: 29804819
[TBL] [Abstract][Full Text] [Related]
8. Disease specific signature of circulating miR-150-5p and miR-21-5p in myasthenia gravis patients.
Punga AR; Andersson M; Alimohammadi M; Punga T
J Neurol Sci; 2015 Sep; 356(1-2):90-6. PubMed ID: 26095457
[TBL] [Abstract][Full Text] [Related]
9. Circulating microRNA plasma profile in MuSK+ myasthenia gravis.
Sabre L; Guptill JT; Russo M; Juel VC; Massey JM; Howard JF; Hobson-Webb LD; Punga AR
J Neuroimmunol; 2018 Dec; 325():87-91. PubMed ID: 30316681
[TBL] [Abstract][Full Text] [Related]
10. Towards Personalized Medicine in Myasthenia Gravis: Role of Circulating microRNAs miR-30e-5p, miR-150-5p and miR-21-5p.
Beretta F; Huang YF; Punga AR
Cells; 2022 Feb; 11(4):. PubMed ID: 35203389
[TBL] [Abstract][Full Text] [Related]
11. [Clinical features of myasthenia related with autoantibodies to muscle specific tyrosine kinase (MuSK)].
Sanadze AG; Sidnev DV; Karganov MIu
Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(12):72-6. PubMed ID: 21311492
[TBL] [Abstract][Full Text] [Related]
12. Analysis of serum miRNA profiles of myasthenia gravis patients.
Nogales-Gadea G; Ramos-Fransi A; Suárez-Calvet X; Navas M; Rojas-García R; Mosquera JL; Díaz-Manera J; Querol L; Gallardo E; Illa I
PLoS One; 2014; 9(3):e91927. PubMed ID: 24637658
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA signature associated with treatment response in myasthenia gravis: A further step towards precision medicine.
Cavalcante P; Mizrachi T; Barzago C; Scandiffio L; Bortone F; Bonanno S; Frangiamore R; Mantegazza R; Bernasconi P; Brenner T; Vaknin-Dembinsky A; Antozzi C
Pharmacol Res; 2019 Oct; 148():104388. PubMed ID: 31401213
[TBL] [Abstract][Full Text] [Related]
14. Muscle-Specific Receptor Tyrosine Kinase (MuSK) Myasthenia Gravis.
Hurst RL; Gooch CL
Curr Neurol Neurosci Rep; 2016 Jul; 16(7):61. PubMed ID: 27170368
[TBL] [Abstract][Full Text] [Related]
15. Low-dose rituximab lowers serum Exosomal miR-150-5p in AChR-positive refractory myasthenia gravis patients.
Zhong H; Lu J; Jing S; Xi J; Yan C; Song J; Luo S; Zhao C
J Neuroimmunol; 2020 Nov; 348():577383. PubMed ID: 32961347
[TBL] [Abstract][Full Text] [Related]
16. miR-30e-5p as predictor of generalization in ocular myasthenia gravis.
Sabre L; Maddison P; Wong SH; Sadalage G; Ambrose PA; Plant GT; Punga AR
Ann Clin Transl Neurol; 2019 Feb; 6(2):243-251. PubMed ID: 30847357
[TBL] [Abstract][Full Text] [Related]
17. Myasthenia gravis experimentally induced with muscle-specific kinase.
Shigemoto K; Kubo S; Jie C; Hato N; Abe Y; Ueda N; Kobayashi N; Kameda K; Mominoki K; Miyazawa A; Ishigami A; Matsuda S; Maruyama N
Ann N Y Acad Sci; 2008; 1132():93-8. PubMed ID: 18096854
[TBL] [Abstract][Full Text] [Related]
18. Circulating miRNAs in myasthenia gravis: miR-150-5p as a new potential biomarker.
Punga T; Le Panse R; Andersson M; Truffault F; Berrih-Aknin S; Punga AR
Ann Clin Transl Neurol; 2014 Jan; 1(1):49-58. PubMed ID: 25356381
[TBL] [Abstract][Full Text] [Related]
19. Circulating miR-23b-3p, miR-145-5p and miR-200b-3p are potential biomarkers to monitor acute pain associated with laminitis in horses.
Lecchi C; Dalla Costa E; Lebelt D; Ferrante V; Canali E; Ceciliani F; Stucke D; Minero M
Animal; 2018 Feb; 12(2):366-375. PubMed ID: 28689512
[TBL] [Abstract][Full Text] [Related]
20. Flow Cytofluorimetric Analysis of Anti-LRP4 (LDL Receptor-Related Protein 4) Autoantibodies in Italian Patients with Myasthenia Gravis.
Marino M; Scuderi F; Samengo D; Saltelli G; Maiuri MT; Shen C; Mei L; Sabatelli M; Pani G; Antonini G; Evoli A; Bartoccioni E
PLoS One; 2015; 10(8):e0135378. PubMed ID: 26284792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
